NCT00367393

Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis

An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Pimecrolimus cream 1%	Pimecrolimus cream 1% bid, as needed

Timeline

• Start date: 2006-03-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2006-08-22
• Last updated: 2017-02-24

Locations

1 site across 1 country: Germany